Hyperlipoproteinemia Type II Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major hyperlipoproteinemia type II markets are expected to exhibit a CAGR of 6.79% during 2024-2034.
The hyperlipoproteinemia type II market has been comprehensively analyzed in IMARC's new report titled "Hyperlipoproteinemia Type II Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperlipoproteinemia type II, also known as familial hypercholesterolemia (FH), is a genetic condition characterized by high cholesterol concentrations, specifically elevated levels of low-density lipoprotein (LDL), often referred to as bad cholesterol. The most typical symptom of this illness includes yellowish, raised nodules under the skin, particularly around the eyes, elbows, knees, and tendons. Additionally, individuals suffering from the ailment have a significantly higher risk of developing premature coronary artery disease, heart attacks, and strokes. In some cases, hyperlipoproteinemia type II can lead to clouding of the cornea, affecting the vision. The diagnosis of this condition is usually made through a combination of clinical evaluation, review of personal and family medical history, and lipid profile analysis. The healthcare provider may perform a physical examination to assess any signs of FH, such as fatty deposits under the skin or around the eyes. Genetic testing may also be used to confirm the diagnosis and identify specific gene mutations associated with the disease. Numerous other investigations, like electrocardiograms, echocardiography, stress tests, etc., might be required to evaluate the extent of cardiovascular risk in patients.
The rising cases of genetic mutations, which can affect the body's ability to efficiently remove LDL cholesterol from the blood, thereby leading to its accumulation, are primarily driving the hyperlipoproteinemia type II market. In addition to this, the increasing incidence of various associated risk factors, including obesity, sedentary lifestyle, consumption of a diet high in saturated and trans fats, metabolic syndrome, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as atorvastatin, simvastatin, rosuvastatin, etc., since they work by blocking an enzyme responsible for cholesterol synthesis in the liver, leading to a reduction in LDL levels, is further bolstering the market growth. Apart from this, the inflating popularity of apheresis procedures owing to their numerous advantages, like symptom relief, improved quality of life, and reduced cardiovascular risk, is acting as another significant growth-inducing factor. Additionally, the emerging application of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors via subcutaneous injections to enhance treatment adherence compared to several other injectable medications is expected to drive the hyperlipoproteinemia type II market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hyperlipoproteinemia type II market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperlipoproteinemia type II and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperlipoproteinemia type II market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hyperlipoproteinemia type II market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hyperlipoproteinemia type II market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hyperlipoproteinemia type II marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hyperlipoproteinemia type II market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hyperlipoproteinemia type II market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hyperlipoproteinemia type II market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hyperlipoproteinemia type II across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperlipoproteinemia type II by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperlipoproteinemia type II by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hyperlipoproteinemia type II across the seven major markets?
What is the size of the hyperlipoproteinemia type II patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hyperlipoproteinemia type II?
What will be the growth rate of patients across the seven major markets?
Hyperlipoproteinemia Type II: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hyperlipoproteinemia type II drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperlipoproteinemia type II market?
What are the key regulatory events related to the hyperlipoproteinemia type II market?
What is the structure of clinical trial landscape by status related to the hyperlipoproteinemia type II market?
What is the structure of clinical trial landscape by phase related to the hyperlipoproteinemia type II market?
What is the structure of clinical trial landscape by route of administration related to the hyperlipoproteinemia type II market?
The hyperlipoproteinemia type II market has been comprehensively analyzed in IMARC's new report titled "Hyperlipoproteinemia Type II Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Hyperlipoproteinemia type II, also known as familial hypercholesterolemia (FH), is a genetic condition characterized by high cholesterol concentrations, specifically elevated levels of low-density lipoprotein (LDL), often referred to as bad cholesterol. The most typical symptom of this illness includes yellowish, raised nodules under the skin, particularly around the eyes, elbows, knees, and tendons. Additionally, individuals suffering from the ailment have a significantly higher risk of developing premature coronary artery disease, heart attacks, and strokes. In some cases, hyperlipoproteinemia type II can lead to clouding of the cornea, affecting the vision. The diagnosis of this condition is usually made through a combination of clinical evaluation, review of personal and family medical history, and lipid profile analysis. The healthcare provider may perform a physical examination to assess any signs of FH, such as fatty deposits under the skin or around the eyes. Genetic testing may also be used to confirm the diagnosis and identify specific gene mutations associated with the disease. Numerous other investigations, like electrocardiograms, echocardiography, stress tests, etc., might be required to evaluate the extent of cardiovascular risk in patients.
The rising cases of genetic mutations, which can affect the body's ability to efficiently remove LDL cholesterol from the blood, thereby leading to its accumulation, are primarily driving the hyperlipoproteinemia type II market. In addition to this, the increasing incidence of various associated risk factors, including obesity, sedentary lifestyle, consumption of a diet high in saturated and trans fats, metabolic syndrome, etc., is creating a positive outlook for the market. Moreover, the widespread adoption of effective medications, such as atorvastatin, simvastatin, rosuvastatin, etc., since they work by blocking an enzyme responsible for cholesterol synthesis in the liver, leading to a reduction in LDL levels, is further bolstering the market growth. Apart from this, the inflating popularity of apheresis procedures owing to their numerous advantages, like symptom relief, improved quality of life, and reduced cardiovascular risk, is acting as another significant growth-inducing factor. Additionally, the emerging application of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors via subcutaneous injections to enhance treatment adherence compared to several other injectable medications is expected to drive the hyperlipoproteinemia type II market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the hyperlipoproteinemia type II market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for hyperlipoproteinemia type II and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the hyperlipoproteinemia type II market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the hyperlipoproteinemia type II market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the hyperlipoproteinemia type II market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current hyperlipoproteinemia type II marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the hyperlipoproteinemia type II market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the hyperlipoproteinemia type II market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the hyperlipoproteinemia type II market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of hyperlipoproteinemia type II across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperlipoproteinemia type II by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of hyperlipoproteinemia type II by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with hyperlipoproteinemia type II across the seven major markets?
What is the size of the hyperlipoproteinemia type II patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of hyperlipoproteinemia type II?
What will be the growth rate of patients across the seven major markets?
Hyperlipoproteinemia Type II: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for hyperlipoproteinemia type II drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the hyperlipoproteinemia type II market?
What are the key regulatory events related to the hyperlipoproteinemia type II market?
What is the structure of clinical trial landscape by status related to the hyperlipoproteinemia type II market?
What is the structure of clinical trial landscape by phase related to the hyperlipoproteinemia type II market?
What is the structure of clinical trial landscape by route of administration related to the hyperlipoproteinemia type II market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERLIPOPROTEINEMIA TYPE II - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERLIPOPROTEINEMIA TYPE II - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERLIPOPROTEINEMIA TYPE II - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HYPERLIPOPROTEINEMIA TYPE II - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERLIPOPROTEINEMIA TYPE II - UNMET NEEDS
10 HYPERLIPOPROTEINEMIA TYPE II - KEY ENDPOINTS OF TREATMENT
11 HYPERLIPOPROTEINEMIA TYPE II - MARKETED PRODUCTS
11.1 List of Hyperlipoproteinemia Type II Marketed Drugs Across the Top 7 Markets
11.1.1 Atorvastatin calcium suspension (ATORVALIQ) - CMP Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 MK-733 (Simvastatin) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Evinacumab - Regeneron Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPERLIPOPROTEINEMIA TYPE II - PIPELINE DRUGS
12.1 List of Hyperlipoproteinemia Type II Pipeline Drugs Across the Top 7 Markets
12.1.1 MGL-3196 (Resmetirom) - Madrigal Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MBX 8025 (Seladelpar) - CymaBay Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 HYPERLIPOPROTEINEMIA TYPE II - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HYPERLIPOPROTEINEMIA TYPE II – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERLIPOPROTEINEMIA TYPE II - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hyperlipoproteinemia Type II - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hyperlipoproteinemia Type II - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hyperlipoproteinemia Type II - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hyperlipoproteinemia Type II - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hyperlipoproteinemia Type II - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hyperlipoproteinemia Type II - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hyperlipoproteinemia Type II - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hyperlipoproteinemia Type II - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
16 HYPERLIPOPROTEINEMIA TYPE II - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERLIPOPROTEINEMIA TYPE II MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERLIPOPROTEINEMIA TYPE II MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 HYPERLIPOPROTEINEMIA TYPE II - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 HYPERLIPOPROTEINEMIA TYPE II - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 HYPERLIPOPROTEINEMIA TYPE II - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 HYPERLIPOPROTEINEMIA TYPE II - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 HYPERLIPOPROTEINEMIA TYPE II - UNMET NEEDS
10 HYPERLIPOPROTEINEMIA TYPE II - KEY ENDPOINTS OF TREATMENT
11 HYPERLIPOPROTEINEMIA TYPE II - MARKETED PRODUCTS
11.1 List of Hyperlipoproteinemia Type II Marketed Drugs Across the Top 7 Markets
11.1.1 Atorvastatin calcium suspension (ATORVALIQ) - CMP Pharma
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 MK-733 (Simvastatin) - Merck & Co
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Evinacumab - Regeneron Pharmaceuticals
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 HYPERLIPOPROTEINEMIA TYPE II - PIPELINE DRUGS
12.1 List of Hyperlipoproteinemia Type II Pipeline Drugs Across the Top 7 Markets
12.1.1 MGL-3196 (Resmetirom) - Madrigal Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MBX 8025 (Seladelpar) - CymaBay Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 HYPERLIPOPROTEINEMIA TYPE II - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 HYPERLIPOPROTEINEMIA TYPE II – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 HYPERLIPOPROTEINEMIA TYPE II - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Hyperlipoproteinemia Type II - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Hyperlipoproteinemia Type II - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Hyperlipoproteinemia Type II - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Hyperlipoproteinemia Type II - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Hyperlipoproteinemia Type II - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Hyperlipoproteinemia Type II - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Hyperlipoproteinemia Type II - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Hyperlipoproteinemia Type II - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Hyperlipoproteinemia Type II - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Hyperlipoproteinemia Type II - Access and Reimbursement Overview
16 HYPERLIPOPROTEINEMIA TYPE II - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 HYPERLIPOPROTEINEMIA TYPE II MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 HYPERLIPOPROTEINEMIA TYPE II MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
